1. Home
  2. ACA vs BLTE Comparison

ACA vs BLTE Comparison

Compare ACA & BLTE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Arcosa Inc.

ACA

Arcosa Inc.

SELL

Current Price

$147.02

Market Cap

7.2B

Sector

Industrials

ML Signal

SELL

Logo Belite Bio Inc

BLTE

Belite Bio Inc

SELL

Current Price

$144.94

Market Cap

6.0B

Sector

Health Care

ML Signal

SELL

Company Overview

Basic Information
Metric
ACA
BLTE
Founded
2018
2018
Country
United States
United States
Employees
N/A
N/A
Industry
Metal Fabrications
Biotechnology: Pharmaceutical Preparations
Sector
Industrials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
7.2B
6.0B
IPO Year
2018
2021

Fundamental Metrics

Financial Performance
Metric
ACA
BLTE
Price
$147.02
$144.94
Analyst Decision
Hold
Strong Buy
Analyst Count
3
9
Target Price
$146.67
★ $228.89
AVG Volume (30 Days)
★ 600.4K
130.5K
Earning Date
10-29-2026
11-09-2026
Dividend Yield
★ 0.14%
N/A
EPS Growth
★ 121.99
N/A
EPS
★ 7.43
N/A
Revenue
★ $2,883,400,000.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
$9.65
N/A
P/E Ratio
$19.79
★ N/A
Revenue Growth
★ 12.20
N/A
52 Week Low
$91.40
$86.57
52 Week High
$147.50
$200.00

Technical Indicators

Market Signals
Indicator
ACA
BLTE
Relative Strength Index (RSI) 64.32 32.57
Support Level $144.75 $132.50
Resistance Level N/A $161.10
Average True Range (ATR) 0.45 5.72
MACD 0.00 -1.53
Stochastic Oscillator 70.00 10.67

Price Performance

Historical Comparison
ACA
BLTE

About ACA Arcosa Inc.

Arcosa Inc is a manufacturer and producer of infrastructure-related products and solutions in the U.S. It operates in three segments: Construction Products, Engineered Structures, and Transportation Products. Maximum revenue is generated from the Construction Products segment, which produces aggregates, specialty materials, asphalt, and construction support gear. The Engineered Structures segment mainly manufactures and sells steel and concrete structures for infrastructure businesses, including utility structures for electricity transmission and distribution, structural wind towers, traffic and lighting structures, and telecommunication structures; and the Transportation Products segment builds inland barges, fiberglass covers, winches, marine hardware, and other industrial equipment.

About BLTE Belite Bio Inc

Belite Bio Inc is a clinical stage biopharmaceutical drug development company focused on advancing novel therapeutics targeting degenerative retinal diseases which have unmet medical need such as Geographic Atrophy (GA), the late atrophic (dry) form of age-related macular degeneration (AMD), and Stargardt disease type 1 (STGD1). In addition to its product candidate (tinlarebant) which is intended for the treatment of GA and STGD1, its drug development pipeline also includes a small molecule, orally administered compound, LBS-009, which is intended for the treatment of metabolic diseases such as non-alcoholic fatty liver disease (NAFLD), nonalcoholic steatohepatitis (NASH), type 2 diabetes (T2D), and gout.

Share on Social Networks: